JP2024527537A5 - - Google Patents

Info

Publication number
JP2024527537A5
JP2024527537A5 JP2023580373A JP2023580373A JP2024527537A5 JP 2024527537 A5 JP2024527537 A5 JP 2024527537A5 JP 2023580373 A JP2023580373 A JP 2023580373A JP 2023580373 A JP2023580373 A JP 2023580373A JP 2024527537 A5 JP2024527537 A5 JP 2024527537A5
Authority
JP
Japan
Prior art keywords
immune effector
effector cells
seq
target portion
hla
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023580373A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024527537A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/103102 external-priority patent/WO2023274387A1/zh
Publication of JP2024527537A publication Critical patent/JP2024527537A/ja
Publication of JP2024527537A5 publication Critical patent/JP2024527537A5/ja
Pending legal-status Critical Current

Links

JP2023580373A 2021-07-01 2022-06-30 Gd2を標的とするユニバーサルcar-t細胞及びその製造方法並びに使用 Pending JP2024527537A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202110749475 2021-07-01
CN202110749475.0 2021-07-01
PCT/CN2022/103102 WO2023274387A1 (zh) 2021-07-01 2022-06-30 靶向gd2的通用型car-t细胞及其制备方法和应用

Publications (2)

Publication Number Publication Date
JP2024527537A JP2024527537A (ja) 2024-07-25
JP2024527537A5 true JP2024527537A5 (cg-RX-API-DMAC7.html) 2025-07-07

Family

ID=84690472

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023580373A Pending JP2024527537A (ja) 2021-07-01 2022-06-30 Gd2を標的とするユニバーサルcar-t細胞及びその製造方法並びに使用

Country Status (4)

Country Link
US (1) US20240139321A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024527537A (cg-RX-API-DMAC7.html)
CN (1) CN118019842A (cg-RX-API-DMAC7.html)
WO (1) WO2023274387A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023274380A1 (zh) * 2021-07-01 2023-01-05 宁波茂行生物医药科技有限公司 靶向IL13Rα2的通用型CAR-T细胞及其制备方法和应用
WO2025219520A1 (en) * 2024-04-18 2025-10-23 Match Medicines Gmbh MODIFIED HUMAN T CELL WITH A REDUCED HLA-Ia REPERTOIRE AND METHOD OF PRODUCTION

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE471946T1 (de) * 2002-12-17 2010-07-15 Merck Patent Gmbh Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2
WO2013074916A1 (en) * 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
EP4086285A1 (en) * 2016-02-25 2022-11-09 Cell Medica Switzerland AG Binding members to pd-l1
CN110352068A (zh) * 2016-12-02 2019-10-18 南加利福尼亚大学 合成的免疫受体及其使用方法
BR112019023608A2 (pt) * 2017-05-12 2020-05-26 Crispr Therapeutics Ag Materiais e métodos para células manipuladas e seus usos em imuno-oncologia
CA3069527A1 (en) * 2017-07-12 2019-01-17 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for treatment of cancers harboring an h3k27m mutation
CN109456943A (zh) * 2017-09-06 2019-03-12 亘喜生物科技(上海)有限公司 通用型嵌合抗原受体t细胞制备技术
BR112020005938A2 (pt) * 2017-09-27 2020-11-17 University Of Southern California célula imune ou população de células imunes da mesma, célula efetora imune ou célula-tronco, célula que apresenta antígeno, polinucleotídeo recombinante, vetor, composição que compreende uma célula imune efetora ou uma célula-tronco, métodos para produzir uma célula efetora imune que expressa receptor imune de ocorrência não natural, para gerar uma população de células manipuladas por rna, para fornecer imunidade antidoença em um indivíduo, para tratar ou prevenir uma doença associada à expressão de um antígeno, e, uso
CN107630006B (zh) * 2017-09-30 2020-09-11 山东兴瑞生物科技有限公司 一种制备tcr与hla双基因敲除的t细胞的方法
CN107723275B (zh) * 2017-10-20 2020-09-04 重庆精准生物技术有限公司 通用型car-t细胞及其制备方法和应用
CN108728460A (zh) * 2018-05-25 2018-11-02 上海恒润达生生物科技有限公司 靶向gd2的嵌合抗原受体及其用途
CN108948211B (zh) * 2018-07-24 2021-08-20 北京美康基免生物科技有限公司 一种基于靶向gd2的嵌合抗原受体及其应用
CN109096405B (zh) * 2018-09-20 2021-07-09 杭州普略生物科技有限公司 以gd2为靶点的嵌合抗原受体及药物组合物
EP3934666A1 (en) * 2019-03-08 2022-01-12 Autolus Limited Compositions and methods comprising engineered chimeric antigen receptor and modulator of car
CA3138633A1 (en) * 2019-04-30 2020-11-05 Crispr Therapeutics Ag Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19
JP7670358B2 (ja) * 2020-01-02 2025-04-30 寧波茂行生物医薬科技有限公司 修飾された免疫エフェクター細胞及びその調製方法

Similar Documents

Publication Publication Date Title
US20250136700A1 (en) Bispecific antibody for cancer immunotherapy
US20220047633A1 (en) Cd22 chimeric antigen receptor (car) therapies
US20210347851A1 (en) Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
TWI854953B (zh) 抗cd3抗體及含有該抗體的分子、及其製造方法
JP7399852B2 (ja) 多重特異性抗体とその作製及び使用方法
KR20220035367A (ko) 항-dll3 키메라 항원 수용체 및 이의 용도
BR112019016204A2 (pt) anticorpo ou fragmento de ligação a antígeno do anticorpo, polinucleotídeo, vetor, célula, imunócito artificial, métodos para produzir um anticorpo ou um fragmento de ligação a antígeno do anticorpo, para produzir uma molécula que se liga ao cd3 humano e cd3 de macaco cinomolgo e ao gprc5d humano, composição medicinal para tratamento e/ou prevenção, moléculas tendo atividade de ligação a antígeno e que se ligam ao cd3 humano e cd3 de macaco cinomolgo e ao gprc5d humano, e, usos para preparar um medicamento para tratar e/ou prevenir um câncer, para induzir citotoxicidade para as células expressando gprc5d e para redirecionamento de células t para as células expressando gprc5d
TW202340473A (zh) 利用嵌合抗原受體之癌症治療
CN112028996A (zh) 靶向bcma的单域抗体及其用途
JP2018504113A (ja) 共通軽鎖を有する二重特異性抗体又は抗体混合物
TW201708261A (zh) Dll3及cd3抗體構築體
WO2016197497A1 (zh) 一种抗pd-1的单克隆抗体及其获得方法
JP2019530431A5 (cg-RX-API-DMAC7.html)
JP2022542559A5 (cg-RX-API-DMAC7.html)
JP2018162269A (ja) P2x7受容体アンタゴニスト及びアゴニスト
JP2024509910A (ja) Mage-a4ペプチド-mhc抗原結合タンパク質
JP2021072773A (ja) p53−MHCクラスI複合体に結合するT細胞受容体様抗体
TW202346368A (zh) 具有增加的選擇性的多鏈多靶向性雙特異性抗原結合分子
JP2024516308A5 (cg-RX-API-DMAC7.html)
WO2015172341A1 (zh) 针对磷脂酰肌醇蛋白多糖-3和t细胞抗原的双特异性抗体
JP2024012258A (ja) Cd22に特異的なヒト化抗体およびそれを用いたキメラ抗原受容体
JP2025532313A (ja) Cd3を標的とする抗体及びその用途
JP2024527539A5 (cg-RX-API-DMAC7.html)
WO2022002006A1 (zh) Fab-HCAb结构的结合蛋白
US20250092154A1 (en) Anti-mesothelin antibodies and uses thereof